Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Permissions
    • Continuing Education
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Subscribe to JNMT RSS feeds
OtherContinuing Education (Invitation Only)

Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs

Diane K. Soulek, Nic J. Mastascusa, Molly E. Martin and Stephen A. Graves
Journal of Nuclear Medicine Technology June 2022, jnmt.122.263813; DOI: https://doi.org/10.2967/jnmt.122.263813
Diane K. Soulek
University of Iowa Hospitals and Clinics, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nic J. Mastascusa
University of Iowa Hospitals and Clinics, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Molly E. Martin
University of Iowa Hospitals and Clinics, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen A. Graves
University of Iowa Hospitals and Clinics, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen A. Graves
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The 2018 FDA approval of 177Lu-DOTATATE for the treatment of somatostatin receptor-positive (SSTR) neuroendocrine tumors (NETs) represents a paradigm shifting approach to cancer treatments around the globe. Gastroenteropancreatic (GEP) NETs overexpress the somatostatin subtype receptor 2, which is now exploited for receptor-based imaging and therapy, thus generating significant progress in the diagnosis and treatment of this orphan disease. The recent FDA approval of receptor-based PET radiopharmaceuticals and a new peptide receptor radiopharmaceutical therapy (PRRT), 177Lu-DOTATATE, has dramatically impacted NET patient management. The focus of this paper is to review clinical considerations associated with implementing a 177Lu-DOTATATE program. We review receptor-based NET radiopharmaceuticals, 177Lu-DOTATATE patient selection criteria, administration methods, clinical, regulatory, and radiation safety considerations, technical factors, tissue dosimetry, and reimbursement guidelines.

  • CNMT
  • Neuroendocrine
  • PET/CT
  • Radionuclide Therapy
  • 177Lu-DOTATATE
  • PRRT
  • dosimetry
  • neuroendocrine tumor
  • somatostatin receptor

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 50 (2)
Journal of Nuclear Medicine Technology
Vol. 50, Issue 2
June 1, 2022
  • Table of Contents
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
Diane K. Soulek, Nic J. Mastascusa, Molly E. Martin, Stephen A. Graves
Journal of Nuclear Medicine Technology Jun 2022, jnmt.122.263813; DOI: 10.2967/jnmt.122.263813

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Practical Considerations for Implementation of 177Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
Diane K. Soulek, Nic J. Mastascusa, Molly E. Martin, Stephen A. Graves
Journal of Nuclear Medicine Technology Jun 2022, jnmt.122.263813; DOI: 10.2967/jnmt.122.263813
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer— Use of Imaging Agents in Therapeutic Drug Development and Approval
  • Diuretic Renal Scintigraphy Protocol Considerations
Show more Continuing Education (Invitation Only)

Similar Articles

Keywords

  • CNMT
  • Neuroendocrine
  • PET/CT
  • Radionuclide Therapy
  • 177Lu-DOTATATE
  • PRRT
  • dosimetry
  • neuroendocrine tumor
  • somatostatin receptor
SNMMI

© 2022 Journal of Nuclear Medicine Technology

Powered by HighWire